Trial Profile

A Multicenter, Open-Label Study to Investigate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary)
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

09 May 2024 Status changed from recruiting to completed.
23 Aug 2022 Planned primary completion date changed from 28 Feb 2022 to 28 Feb 2023.
23 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com